Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of galinpepimut-S in combination with pembrolizumab
in patients with selected advanced cancers. Patients will be followed long-term for Overall
Survival (OS) and safety. The study will enroll approximately 90 patients and maximum study
treatment duration is approximately 2.13 years.